Alan Anthoney

16.0k total citations · 1 hit paper
108 papers, 6.6k citations indexed

About

Alan Anthoney is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Alan Anthoney has authored 108 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 27 papers in Molecular Biology. Recurrent topics in Alan Anthoney's work include Pancreatic and Hepatic Oncology Research (28 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers) and Colorectal Cancer Treatments and Studies (13 papers). Alan Anthoney is often cited by papers focused on Pancreatic and Hepatic Oncology Research (28 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers) and Colorectal Cancer Treatments and Studies (13 papers). Alan Anthoney collaborates with scholars based in United Kingdom, United States and France. Alan Anthoney's co-authors include Juan W. Valle, Harpreet Wasan, John Bridgewater, Anthony Maraveyas, David Cunningham, Daniel H. Palmer, Srinivasan Madhusudan, Timothy Iveson, Sy Ha and S. Hughes and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Alan Anthoney

104 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

2010 3.0k citations Juan W. Valle, Harpreet Wasan et al. profile →

Peers

Countries citing papers authored by Alan Anthoney

Since Specialization

Citations

This map shows the geographic impact of Alan Anthoney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Anthoney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Anthoney more than expected).

Fields of papers citing papers by Alan Anthoney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Anthoney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Anthoney. The network helps show where Alan Anthoney may publish in the future.

Co-authorship network of co-authors of Alan Anthoney

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Anthoney. A scholar is included among the top collaborators of Alan Anthoney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Anthoney. Alan Anthoney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	622 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099318, in patients with select advanced solid tumors 2022 ·Regular and Young Investigator Award Abstracts ·David J. Pinato, Ruth Plummer, Martin Gutierrez, Jeffrey Yachnin, (unknown), Martin Højgaard, Knut B. Smeland, William J. Edenfield, Hans Prenen, Lars Ny, Alan Anthoney, Nuria Kotecki, Stefan N. Symeonides, Louis Viviers, (unknown), (unknown), Udai Banerji	3
2	A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer 2022 ·Clinical Cancer Research ·Robert H. Jones, Ruth Plummer, Víctor Moreno, Louise Carter, Desamparados Roda, Elena Garralda, Rebecca Kristeleit, Debashis Sarker, Hendrik‐Tobias Arkenau, Patricia Roxburgh, Harriet S. Walter, Sarah P. Blagden, Alan Anthoney, Barbara Klencke, Mark Kowalski, Udai Banerji	27
3	Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma 2020 ·Clinical Cancer Research ·Mark R. Middleton, Cheryl McAlpine, Victoria K. Woodcock, Pippa Corrie, Jeffrey R. Infante, Neil Steven, T.R. Jeffry Evans, Alan Anthoney, Alexander N. Shoushtari, Omid Hamid, Avinash Gupta, Antonella Vardeu, Emma Leach, Revashnee Naidoo, (unknown), Sion Lewis, Jacob Hurst, Anne M. Kelly, Mario Sznol	165
4	The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study 2019 ·Journal of Gastrointestinal Surgery ·George Papaxoinis, Konstantinos Kamposioras, Jamie Weaver, (unknown), (unknown), (unknown), (unknown), (unknown), Alan Anthoney, Wasat Mansoor	12
5	Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial 2018 ·British Journal of Cancer ·Alison Backen, Andre Lopes, Harpreet Wasan, Daniel H. Palmer, Marian Duggan, David Cunningham, Alan Anthoney, Pippa Corrie, Srinivasan Madhusudan, Anthony Maraveyas, Paul J. Ross, Justin S. Waters, William P. Steward, Charlotte Rees, Mairéad G. McNamara, Sandy Beare, John Bridgewater, Caroline Dive, Juan W. Valle	22
6	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial 2017 ·European Journal of Cancer ·Patrick Schöffski, Agnieszka Woźniak, Bernard Escudier, Piotr Rutkowski, Alan Anthoney, Sebastian Bauer, Jozef Šufliarský, Carla van Herpen, Lars H. Lindner, Viktor Grünwald, Branko Zakotnik, Evelyne Lerut, Maria Dêbiec‐Rychter, Sandrine Marréaud, Michela Lia, Tiana Raveloarivahy, Sandra Collette, Laurence Albigès	94
7	Capecitabine and streptozocin ± cisplatin for gastroenteropancreatic neuroendocrine tumours: predictors of long-term survival in the NET01 trial 2016 ·Annals of Oncology ·(unknown), W. Qian, Juan W. Valle, Denis Talbot, David Cunningham, Nick Reed, Lucy Wall, Justin S. Waters, Paul J. Ross, Alan Anthoney, Kate Sumpter, Naveed Sarwar, Tom Crosby, Nehara Begum, Gareth T. Young, (unknown), Pippa Corrie	2
8	First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer 2014 ·Clinical Cancer Research ·Sarah P. Blagden, (unknown), Debra H. Josephs, Chara Stavraka, Andrea Zivi, David J. Pinato, Alan Anthoney, Shaun Decordova, Karen E. Swales, Ruth Riisnaes, Lorna Pope, Kohei Noguchi, (unknown), (unknown), (unknown), Keith Jones, Chris Twelves, James Spicer, Udai Banerji	36
9	Complications of systemic therapy – gut infections and acute diarrhoea 2014 ·Clinical Medicine ·(unknown), Alan Anthoney	2
10	Effects of Tasisulam Sodium on the Pharmacokinetics of Tolbutamide in Patients with Advanced Solid Tumours 2013 ·Annals of Oncology ·Chris Twelves, (unknown), Alan Anthoney, Jill Chappell, (unknown), (unknown), Rebecca Kristeleit	1
11	Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses 2012 ·BMC Cancer ·Alan Anthoney, Jay Naik, Iain R. Macpherson, (unknown), (unknown), (unknown), Tomohisa Saito, (unknown), Keith Jones, Masanori Miwa, Christopher Twelves, (unknown)	8
12	Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study 2008 ·Clinical Cancer Research ·Mark R. Albertella, Paul M. Loadman, Philip H. Jones, Roger M. Phillips, R. Rampling, N.G. Burnet, (unknown), Alan Anthoney, Egils Vjaters, Chris R. Dunk, Peter A. Harris, Alvin Wong, Alshad S. Lalani, Chris Twelves	98
13	Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma 2006 ·British Journal of Cancer ·Stephen Falk, Alan Anthoney, Martin Eatock, Eric Van Cutsem, (unknown), Hilary Glen, Juan W. Valle, Daniel W. Drolet, Donald G. Albert, D. Ferry, Jaffer A. Ajani	10
14	MMP-10 Is Overexpressed, Proteolytically Active, and a Potential Target for Therapeutic Intervention in Human Lung Carcinomas 2004 ·Neoplasia ·Jason H. Gill, (unknown), Jill M. Seargent, (unknown), (unknown), (unknown), Alan J. Mearns, Michael C. Bibby, Alan Anthoney, Paul M. Loadman	57
15	Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours 2003 ·European Journal of Cancer ·Chris Twelves, Klaas Hoekman, A. Bowman, Jan B. Vermorken, Alan Anthoney, John Smyth, Charlotte van Kesteren, Jos H. Beijnen, (unknown), J. Wanders, Javier Gómez, C. Guzmán, José Jimeno, A.-R. Hanauske	75
16	A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies 2003 ·Cancer Chemotherapy and Pharmacology ·Chris Twelves, Martin Reck, Alan Anthoney, U. Gatzemeier, Stan B. Kaye	5
17	A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer 2002 ·British Journal of Cancer ·T.R. Jeffry Evans, K W Colston, F. Lofts, David Cunningham, Alan Anthoney, Helen Gogas, Johann S. de Bono, (unknown), Torsten Skov, Janine Mansi	106
18	DNA: Still A Target Worth Aiming At? 2001 ·PubMed ·Alan Anthoney, Chris Twelves	6
19	Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT) 2000 ·British Journal of Cancer ·Johann S. de Bono, James Paul, (unknown), Alan Anthoney, D. Kirk, Mark A. Underwood, John D. Graham, S.B. Kaye	6
20	hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents 1997 ·Oncogene ·Robert Brown, Gillian L. Hirst, William M. Gallagher, (unknown), Geoffrey P. Margison, Ate GJ van der Zee, Alan Anthoney	208

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact